Fluorescently tagged nucleotides have a wide array of uses; however, methods of quantifying said nucleotides are lacking. The present invention features compositions and methods for quantifying cellular dyes within a sample. Compositions described herein comprise an oligonucleotide barcode conjugated to a cellular dye.

Assays and methods for verifying the validity of a urine sample submitted for Drugs of Abuse (DOA) testing. Embodiments include a SUD Diagnostic Panel that includes six assays: specific gravity index assay, long-duration counterfeit urine assay, short-duration counterfeit urine assay, oxidant history assay, pH assay, and creatinine assay. The SUD Diagnostic Panel detects twelve principle classes of adulteration. Detection of adulteration of one or more urine samples from a patient indicates an attempt to subvert test results and provides an objective indication in one instance and an object diagnosis in another instance of SUD.

The present description provides methods, assays and reagents useful for sequencing proteins. Sequencing proteins in a broad sense involves observing the plausible identity and order of amino acids, which is useful for sequencing single polypeptide molecules or multiple molecules of a single polypeptide. In one aspect, the methods are useful for sequencing multiple polypeptides. The methods and reagents described herein can be useful for high resolution interrogation of the proteome and enabling ultrasensitive diagnostics critical for early detection of diseases.

Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.

The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

A diagnostic test kit is provided. In one aspect, the diagnostic test kit includes a diagnostic test including a test region for indicating a test result. The diagnostic test kit also includes a scan surface including one or more control markings. The one or more control markings are representative of one or more predetermined test results for the diagnostic test. The diagnostic test can include a lateral flow immunoassay test, and the one or more control markings can include one or more lines. The one or more lines can vary in at least one of thickness, color, hue, and reflectivity.

A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

The present disclosure is directed at an antibody conjugate having an antibody and a tag, wherein one or more element(s) present in the antibody exhibit an isotope ratio which differs from the naturally occurring isotope ratio of the one or more element(s), wherein the amount of the isotope which is less-common in nature, is increased to at least 4% of the atoms of the respective element in the antibody, as well as uses thereof.

An exemplar system, and computer-accessible medium for determining phenotypic (e.g., multi-parameter) information for a cell(s) can include, for example, generating spectral information of the cell(s) using a Raman spectroscopy procedure that is based on a vibrational probe(s), and determining the metabolic, protein biomarker, or signaling pathway information based on the spectral information. The Raman spectroscopy procedure can be a single-cell spontaneous Raman spectroscopy procedure. The single-cell Raman spectroscopy procedure can be performed using a whole-cell confocal micro-Raman spectrometer. The vibrational probe(s) can include a Deuterium-labeled branched-chain amino acid(s), or a deuterium-labeled palmitic acid(s), Raman active nanoparticles or other essential metabolites such as glucose and water.

Systems, kits, methods to diagnose sarcoidosis are described. In addition to diagnosing sarcoidosis, the systems and methods can distinguish sarcoidosis from tuberculosis and lung cancer.